{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:58:48Z","timestamp":1772067528160,"version":"3.50.1"},"reference-count":144,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chest"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.chest.2018.07.005","type":"journal-article","created":{"date-parts":[[2018,7,18]],"date-time":"2018-07-18T08:03:03Z","timestamp":1531900983000},"page":"1404-1415","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Pharmacological Therapy of COPD"],"prefix":"10.1016","volume":"154","author":[{"given":"Bartolome R.","family":"Celli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.chest.2018.07.005_bib1","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1164\/rccm.201701-0218PP","article-title":"Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary","volume":"195","author":"Vogelmeier","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"9589","key":"10.1016\/j.chest.2018.07.005_bib2","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0140-6736(07)61377-4","article-title":"International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study","volume":"370","author":"Buist","year":"2007","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.chest.2018.07.005_bib3","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1183\/09031936.00171614","article-title":"COPD comorbidities network","volume":"46","author":"Divo","year":"2015","journal-title":"Eur Respir J"},{"issue":"9589","key":"10.1016\/j.chest.2018.07.005_bib4","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(07)61383-X","article-title":"From COPD to chronic systemic inflammatory syndrome?","volume":"370","author":"Fabbri","year":"2007","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.chest.2018.07.005_bib5","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1378\/chest.14-0972","article-title":"Total and state-specific medical and absenteeism costs of COPD among adults aged\u00a0\u226518 years in the United States for 2010 and projections through 2020","volume":"147","author":"Ford","year":"2015","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.chest.2018.07.005_bib6","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1183\/09031936.06.00024505","article-title":"Epidemiology and costs of chronic obstructive pulmonary disease","volume":"27","author":"Chapman","year":"2006","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.chest.2018.07.005_bib7","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/15412550802237531","article-title":"COPD as a lung disease with systemic consequences--clinical impact, mechanisms, and potential for early intervention","volume":"5","author":"Decramer","year":"2008","journal-title":"COPD"},{"issue":"2","key":"10.1016\/j.chest.2018.07.005_bib8","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1183\/09031936.00208613","article-title":"Disease progression in young patients with COPD: rethinking the Fletcher and Peto model","volume":"44","author":"Sanchez-Salcedo","year":"2014","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.chest.2018.07.005_bib9","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1378\/chest.118.3.697","article-title":"Functional status and survival following pulmonary rehabilitation","volume":"118","author":"Bowen","year":"2000","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.chest.2018.07.005_bib10","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1136\/thx.2006.072348","article-title":"Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee","volume":"62","author":"McGarvey","year":"2007","journal-title":"Thorax"},{"issue":"2","key":"10.1016\/j.chest.2018.07.005_bib11","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1164\/rccm.201201-0034OC","article-title":"Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease","volume":"186","author":"Divo","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"10.1016\/j.chest.2018.07.005_bib12","first-page":"1120","article-title":"Discrepancy in the use of confirmatory tests in patients hospitalized with the diagnosis of chronic obstructive pulmonary disease or congestive heart failure","volume":"51","author":"Damarla","year":"2006","journal-title":"Respir Care"},{"key":"10.1016\/j.chest.2018.07.005_bib13","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.2147\/COPD.S136711","article-title":"Perception of symptoms and quality of life - comparison of patients' and physicians' views in the COPD MIRROR study","volume":"12","author":"Celli","year":"2017","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"4","key":"10.1016\/j.chest.2018.07.005_bib14","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1183\/09031936.02.03242002","article-title":"Impact of COPD in North America and Europe in 2000: subjects' perspective of Confronting COPD International Survey","volume":"20","author":"Rennard","year":"2002","journal-title":"Eur Respir J"},{"key":"10.1016\/j.chest.2018.07.005_bib15","first-page":"1","article-title":"Undertreatment of COPD: a retrospective analysis of US managed care and Medicare patients","volume":"7","author":"Make","year":"2012","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"2","key":"10.1016\/j.chest.2018.07.005_bib16","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1513\/pats.2306033","article-title":"Lessons from the Lung Health Study","volume":"1","author":"Anthonisen","year":"2004","journal-title":"Proc Am Thorac Soc"},{"key":"10.1016\/j.chest.2018.07.005_bib17","doi-asserted-by":"crossref","first-page":"391","DOI":"10.7326\/0003-4819-93-3-391","article-title":"Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group","volume":"93","year":"1980","journal-title":"Ann Intern Med"},{"issue":"8222","key":"10.1016\/j.chest.2018.07.005_bib18","first-page":"681","article-title":"Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party","volume":"1","year":"1981","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.chest.2018.07.005_bib19","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1378\/chest.14-1216","article-title":"Trends in mechanical ventilation among patients hospitalized with acute exacerbations of COPD in the United States, 2001 to 2011","volume":"147","author":"Stefan","year":"2015","journal-title":"Chest"},{"key":"10.1016\/j.chest.2018.07.005_bib20","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02426-2016","article-title":"Official ERS\/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure","author":"Rochwerg","year":"2017","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.chest.2018.07.005_bib21","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.athoracsur.2006.05.069","article-title":"Long-term follow-up of patients receiving lung-volume-reduction surgery versus medical therapy for severe emphysema by the National Emphysema Treatment Trial Research Group","volume":"82","author":"Naunheim","year":"2006","journal-title":"Ann Thorac Surg"},{"issue":"5","key":"10.1016\/j.chest.2018.07.005_bib22","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1164\/rccm.201603-0602OC","article-title":"Benefits of long-term pulmonary rehabilitation maintenance program in patients with severe chronic obstructive pulmonary disease. Three-year follow-up","volume":"195","author":"Guell","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.chest.2018.07.005_bib23","first-page":"CD003793","article-title":"Pulmonary rehabilitation for chronic obstructive pulmonary disease","volume":"23","author":"McCarthy","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"10.1016\/j.chest.2018.07.005_bib24","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1001\/jama.2015.280","article-title":"Effect of varenicline on smoking cessation through smoking reduction: a randomized clinical trial","volume":"313","author":"Ebbert","year":"2015","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.chest.2018.07.005_bib25","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/0735-1097(88)90486-X","article-title":"Smoking cessation strategies and evaluation","volume":"12","author":"Kottke","year":"1988","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.chest.2018.07.005_bib26","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1001\/archgenpsychiatry.2009.142","article-title":"A\u00a0randomized placebo-controlled clinical trial of 5 smoking cessation pharmacotherapies","volume":"66","author":"Piper","year":"2009","journal-title":"Arch Gen Psychiatry"},{"issue":"4","key":"10.1016\/j.chest.2018.07.005_bib27","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1183\/09031936.00129607","article-title":"Bronchodilator responsiveness in patients with COPD","volume":"31","author":"Tashkin","year":"2008","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.chest.2018.07.005_bib28","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1080\/15412550903156333","article-title":"Combination of formoterol and tiotropium in the treatment of COPD: effects on lung function","volume":"6","author":"Cazzola","year":"2009","journal-title":"COPD"},{"issue":"4","key":"10.1016\/j.chest.2018.07.005_bib29","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/15412550600977478","article-title":"The clinical importance of dynamic lung hyperinflation in COPD","volume":"3","author":"O'Donnell","year":"2006","journal-title":"COPD"},{"issue":"3","key":"10.1016\/j.chest.2018.07.005_bib30","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1378\/chest.127.3.809","article-title":"Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD","volume":"127","author":"Casaburi","year":"2005","journal-title":"Chest"},{"issue":"9696","key":"10.1016\/j.chest.2018.07.005_bib31","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/S0140-6736(09)61298-8","article-title":"Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial","volume":"374","author":"Decramer","year":"2009","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.chest.2018.07.005_bib32","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1164\/rccm.200712-1869OC","article-title":"Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study","volume":"178","author":"Celli","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.chest.2018.07.005_bib33","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1164\/rccm.201610-2086OC","article-title":"Fluticasone furoate, vilanterol and lung function decline in patients with moderate COPD and heightened cardiovascular risk","volume":"197","author":"Calverley","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"10.1016\/j.chest.2018.07.005_bib34","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1056\/NEJMoa1700228","article-title":"Tiotropium in early-stage chronic obstructive pulmonary disease","volume":"377","author":"Zhou","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.chest.2018.07.005_bib35","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1080\/15412550701471231","article-title":"How can we assess outcomes of clinical trials: the MCID approach","volume":"4","author":"Make","year":"2007","journal-title":"COPD"},{"issue":"5","key":"10.1016\/j.chest.2018.07.005_bib36","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.chest.2016.02.646","article-title":"A\u00a0systematic review with meta-analysis of dual bronchodilation with LAMA\/LABA for the treatment of stable COPD","volume":"149","author":"Calzetta","year":"2016","journal-title":"Chest"},{"issue":"9","key":"10.1016\/j.chest.2018.07.005_bib37","first-page":"CD006829","article-title":"Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease","volume":"12","author":"Nannini","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1016\/j.chest.2018.07.005_bib38","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1053\/rmed.2002.1455","article-title":"Bronchodilator effect of an inhaled combination therapy with salmeterol\u00a0+ fluticasone and formoterol\u00a0+ budesonide in patients with COPD","volume":"97","author":"Cazzola","year":"2003","journal-title":"Respir Med"},{"issue":"4","key":"10.1016\/j.chest.2018.07.005_bib39","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1152\/japplphysiol.01470.2005","article-title":"Sensory-mechanical relationships during high-intensity, constant-work-rate exercise in COPD","volume":"101","author":"O'Donnell","year":"2006","journal-title":"J\u00a0Appl Physiol"},{"issue":"6","key":"10.1016\/j.chest.2018.07.005_bib40","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1183\/09031936.04.00116004","article-title":"Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD","volume":"23","author":"O'Donnell","year":"2004","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.chest.2018.07.005_bib41","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1378\/chest.130.3.647","article-title":"Effect of fluticasone propionate\/salmeterol on lung hyperinflation and exercise endurance in COPD","volume":"130","author":"O'Donnell","year":"2006","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.chest.2018.07.005_bib42","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.rmed.2009.09.012","article-title":"Additive effects of transdermal tulobuterol to inhaled tiotropium in patients with COPD","volume":"104","author":"Ichinose","year":"2010","journal-title":"Respir Med"},{"issue":"4","key":"10.1016\/j.chest.2018.07.005_bib43","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.rmed.2010.11.019","article-title":"Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD","volume":"105","author":"Maltais","year":"2011","journal-title":"Respir Med"},{"issue":"7","key":"10.1016\/j.chest.2018.07.005_bib44","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.rmed.2011.03.014","article-title":"Effect of indacaterol on exercise endurance and lung hyperinflation in COPD","volume":"105","author":"O'Donnell","year":"2011","journal-title":"Respir Med"},{"issue":"7","key":"10.1016\/j.chest.2018.07.005_bib45","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1164\/rccm.201508-1647OC","article-title":"Lung Deflation and Cardiovascular Structure and Function in Chronic Obstructive Pulmonary Disease. A randomized controlled trial","volume":"193","author":"Stone","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.chest.2018.07.005_bib46","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1411532","article-title":"Lung-function trajectories leading to chronic obstructive pulmonary disease","volume":"373","author":"Lange","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"10.1016\/j.chest.2018.07.005_bib47","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1056\/NEJM199906243402503","article-title":"Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease","volume":"340","author":"Pauwels","year":"1999","journal-title":"N\u00a0Engl J Med"},{"issue":"7245","key":"10.1016\/j.chest.2018.07.005_bib48","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1136\/bmj.320.7245.1297","article-title":"Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial","volume":"320","author":"Burge","year":"2000","journal-title":"BMJ"},{"issue":"8","key":"10.1016\/j.chest.2018.07.005_bib49","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJMoa063070","article-title":"Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease","volume":"356","author":"Calverley","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.chest.2018.07.005_bib50","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1056\/NEJMoa0805800","article-title":"A\u00a04-year trial of tiotropium in chronic obstructive pulmonary disease","volume":"359","author":"Tashkin","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"9470","key":"10.1016\/j.chest.2018.07.005_bib51","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/S0140-6736(05)66456-2","article-title":"Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial","volume":"365","author":"Decramer","year":"2005","journal-title":"Lancet"},{"issue":"10030","key":"10.1016\/j.chest.2018.07.005_bib52","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(16)30069-1","article-title":"Fluticasone Furoate and Vilanterol and Survival in Chronic Obstructive Pulmonary Disease With Heightened Cardiovascular Risk (SUMMIT): a double-blind randomised controlled trial","volume":"387","author":"Vestbo","year":"2016","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.chest.2018.07.005_bib53","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1001\/jama.1994.03520190043033","article-title":"Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study","volume":"272","author":"Anthonisen","year":"1994","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.chest.2018.07.005_bib54","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1164\/rccm.201105-0831OC","article-title":"The progression of chronic obstructive pulmonary disease is heterogeneous: the experience of the BODE cohort","volume":"184","author":"Casanova","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"13","key":"10.1016\/j.chest.2018.07.005_bib55","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1056\/NEJMoa1105482","article-title":"Changes in forced expiratory volume in 1 second over time in COPD","volume":"365","author":"Vestbo","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.chest.2018.07.005_bib56","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1164\/rccm.201106-0992OC","article-title":"Hokkaido COPD Cohort Study Investigators. Annual change in pulmonary function and clinical phenotype in chronic obstructive pulmonary disease","volume":"185","author":"Nishimura","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"10.1016\/j.chest.2018.07.005_bib57","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1164\/rccm.201501-0044ST","article-title":"An Official American Thoracic Society\/European Respiratory Society Statement: research questions in chronic obstructive pulmonary disease","volume":"191","author":"Celli","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.chest.2018.07.005_bib58","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1378\/chest.14-2449","article-title":"Differential Effect of Modified Medical Research Council Dyspnea, COPD Assessment Test, and Clinical COPD Questionnaire for Symptoms Evaluation Within the New GOLD Staging and Mortality in COPD","volume":"148","author":"Casanova","year":"2015","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.chest.2018.07.005_bib59","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1378\/chest.121.4.1092","article-title":"Power of outcome measurements to detect clinically significant changes in pulmonary rehabilitation of patients with COPD","volume":"121","author":"de Torres","year":"2002","journal-title":"Chest"},{"issue":"Suppl A","key":"10.1016\/j.chest.2018.07.005_bib60","first-page":"1A","article-title":"Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2008 update - highlights for primary care","volume":"15","author":"O'Donnell","year":"2008","journal-title":"Can Respir J"},{"issue":"3","key":"10.1016\/j.chest.2018.07.005_bib61","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1513\/pats.200601-002SF","article-title":"Improving dyspnea in chronic obstructive pulmonary disease: optimal treatment strategies","volume":"3","author":"Rabe","year":"2006","journal-title":"Proc Am Thorac Soc"},{"issue":"2","key":"10.1016\/j.chest.2018.07.005_bib62","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1183\/09031936.03.00068503a","article-title":"Minimal important difference of the transition dyspnoea index in a multinational clinical trial","volume":"21","author":"Witek","year":"2003","journal-title":"Eur Respir J"},{"issue":"Suppl 12A","key":"10.1016\/j.chest.2018.07.005_bib63","first-page":"49S","article-title":"Clinically meaningful outcomes in patients with chronic obstructive pulmonary disease","volume":"117","author":"ZuWallack","year":"2004","journal-title":"Am J Med"},{"issue":"5","key":"10.1016\/j.chest.2018.07.005_bib64","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1378\/chest.11-2252","article-title":"Comparison of indacaterol with tiotropium or twice-daily long-acting beta -agonists for stable COPD: a systematic review","volume":"142","author":"Rodrigo","year":"2012","journal-title":"Chest"},{"issue":"23","key":"10.1016\/j.chest.2018.07.005_bib65","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1056\/NEJMoa1516385","article-title":"Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD","volume":"374","author":"Wedzicha","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.chest.2018.07.005_bib66","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.pupt.2011.10.006","article-title":"Comparison of three combined pharmacological approaches with tiotropium monotherapy in stable moderate to severe COPD: a systematic review","volume":"25","author":"Rodrigo","year":"2012","journal-title":"Pulm Pharmacol Ther"},{"issue":"18","key":"10.1016\/j.chest.2018.07.005_bib67","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJMoa1713901","article-title":"Once-daily single-inhaler triple versus dual therapy in patients with COPD","volume":"378","author":"Lipson","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.chest.2018.07.005_bib68","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1164\/rccm.201607-1421OC","article-title":"Effect of fluticasone furoate and vilanterol on exacerbations of chronic obstructive pulmonary disease in patients with moderate airflow obstruction","volume":"195","author":"Martinez","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"10.1016\/j.chest.2018.07.005_bib69","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1136\/thx.2009.113662","article-title":"Adherence to inhaled therapy, mortality and hospital admission in COPD","volume":"64","author":"Vestbo","year":"2009","journal-title":"Thorax"},{"issue":"6","key":"10.1016\/j.chest.2018.07.005_bib70","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.pupt.2006.09.001","article-title":"Safety, tolerability and efficacy of indacaterol, a novel once-daily beta(2)-agonist, in patients with COPD: a 28-day randomised, placebo controlled clinical trial","volume":"20","author":"Beier","year":"2007","journal-title":"Pulm Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.chest.2018.07.005_bib71","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1378\/chest.11-2231","article-title":"The efficacy and safety of the novel long-acting beta2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial","volume":"142","author":"Hanania","year":"2012","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.chest.2018.07.005_bib72","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1183\/09031936.00225511","article-title":"Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study","volume":"40","author":"Jones","year":"2012","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.chest.2018.07.005_bib73","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1183\/09031936.05.00140404","article-title":"Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD","volume":"26","author":"van Noord","year":"2005","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.chest.2018.07.005_bib74","first-page":"482","article-title":"Aclidinium bromide, a novel long-acting muscarinic M3 antagonist for the treatment of COPD","volume":"10","author":"Cazzola","year":"2009","journal-title":"Curr Opin Investig Drugs"},{"issue":"9","key":"10.1016\/j.chest.2018.07.005_bib75","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1345\/aph.1C436","article-title":"Long-acting inhaled beta 2-agonists for stable COPD","volume":"37","author":"Dougherty","year":"2003","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.chest.2018.07.005_bib76","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2147\/COPD.S117196","article-title":"The use of multiple respiratory inhalers requiring different inhalation techniques has an adverse effect on COPD outcomes","volume":"12","author":"Bosnic-Anticevich","year":"2017","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"1","key":"10.1016\/j.chest.2018.07.005_bib77","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000363390","article-title":"New inhaler devices - the good, the bad and the ugly","volume":"88","author":"Lavorini","year":"2014","journal-title":"Respiration"},{"issue":"2","key":"10.1016\/j.chest.2018.07.005_bib78","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.chest.2016.03.041","article-title":"Systematic review of errors in inhaler use: has patient technique improved over time?","volume":"150","author":"Sanchis","year":"2016","journal-title":"Chest"},{"issue":"10","key":"10.1016\/j.chest.2018.07.005_bib79","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1164\/rccm.201604-0733OC","article-title":"Objective assessment of adherence to inhalers by patients with chronic obstructive pulmonary disease","volume":"195","author":"Sulaiman","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.chest.2018.07.005_bib80","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1378\/chest.121.5.1434","article-title":"Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD","volume":"121","author":"Nishimura","year":"2002","journal-title":"Chest"},{"issue":"10","key":"10.1016\/j.chest.2018.07.005_bib81","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa021322","article-title":"The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease","volume":"350","author":"Celli","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.chest.2018.07.005_bib82","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1183\/09031936.00102509","article-title":"Development and first validation of the COPD Assessment Test","volume":"34","author":"Jones","year":"2009","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.chest.2018.07.005_bib83","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/2049-6958-5-3-202","article-title":"Measures of dyspnea in pulmonary rehabilitation","volume":"5","author":"Crisafulli","year":"2010","journal-title":"Multidiscip Respir Med"},{"issue":"12","key":"10.1016\/j.chest.2018.07.005_bib84","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1056\/NEJMoa0909883","article-title":"Susceptibility to exacerbation in chronic obstructive pulmonary disease","volume":"363","author":"Hurst","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.chest.2018.07.005_bib85","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1378\/chest.14-0655","article-title":"Hospitalized exacerbations of COPD: risk factors and outcomes in the ECLIPSE cohort","volume":"147","author":"Mullerova","year":"2015","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.chest.2018.07.005_bib86","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.chest.2016.01.026","article-title":"Blood eosinophils and outcomes in severe hospitalized exacerbations of COPD","volume":"150","author":"Bafadhel","year":"2016","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.chest.2018.07.005_bib87","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S2213-2600(15)00106-X","article-title":"Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials","volume":"3","author":"Pascoe","year":"2015","journal-title":"Lancet Respir Med"},{"issue":"2","key":"10.1016\/j.chest.2018.07.005_bib88","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1136\/thoraxjnl-2015-207021","article-title":"Blood eosinophils and inhaled corticosteroid\/long-acting beta-2 agonist efficacy in COPD","volume":"71","author":"Pavord","year":"2016","journal-title":"Thorax"},{"issue":"4","key":"10.1016\/j.chest.2018.07.005_bib89","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1164\/rccm.201502-0235LE","article-title":"Blood eosinophils: a biomarker of response to extrafine beclomethasone\/formoterol in chronic obstructive pulmonary disease","volume":"192","author":"Siddiqui","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"10.1016\/j.chest.2018.07.005_bib90","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.arbres.2017.01.011","article-title":"Is the blood eosinophil count a useful biomarker in COPD? The devil is in the details!","volume":"53","author":"Celli","year":"2017","journal-title":"Arch Bronconeumol"},{"issue":"17","key":"10.1016\/j.chest.2018.07.005_bib91","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa1708208","article-title":"Mepolizumab for eosinophilic chronic obstructive pulmonary disease","volume":"377","author":"Pavord","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.chest.2018.07.005_bib92","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S2213-2600(16)30148-5","article-title":"Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis","volume":"4","author":"Pavord","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.chest.2018.07.005_bib93","doi-asserted-by":"crossref","first-page":"629","DOI":"10.2147\/COPD.S61717","article-title":"Efficacy and safety of olodaterol once daily delivered via Respimat(R) in patients with GOLD 2-4 COPD: results from two replicate 48-week studies","volume":"9","author":"Ferguson","year":"2014","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"8","key":"10.1016\/j.chest.2018.07.005_bib94","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1136\/thx.2010.136077","article-title":"Cardiovascular events in patients with COPD: TORCH study results","volume":"65","author":"Calverley","year":"2010","journal-title":"Thorax"},{"issue":"19","key":"10.1016\/j.chest.2018.07.005_bib95","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1136\/heartjnl-2016-310897","article-title":"Cardiovascular outcomes with an inhaled beta2-agonist\/corticosteroid in patients with COPD at high cardiovascular risk","volume":"103","author":"Brook","year":"2017","journal-title":"Heart"},{"issue":"Suppl 12A","key":"10.1016\/j.chest.2018.07.005_bib96","first-page":"33S","article-title":"Lung function improvements with once-daily tiotropium in chronic obstructive pulmonary disease","volume":"117","author":"Casaburi","year":"2004","journal-title":"Am J Med"},{"issue":"5","key":"10.1016\/j.chest.2018.07.005_bib97","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1378\/chest.13-1579","article-title":"Once-daily umeclidinium\/vilanterol 125\/25 mcg in COPD: a randomized, controlled study","volume":"145","author":"Celli","year":"2014","journal-title":"Chest"},{"issue":"10","key":"10.1016\/j.chest.2018.07.005_bib98","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1016\/j.rmed.2013.06.001","article-title":"Efficacy and safety of once-daily umeclidinium\/vilanterol 62.5\/25 mcg in COPD","volume":"107","author":"Donohue","year":"2013","journal-title":"Respir Med"},{"issue":"Suppl 12A","key":"10.1016\/j.chest.2018.07.005_bib99","first-page":"24S","article-title":"The role of anticholinergics in chronic obstructive pulmonary disease","volume":"117","author":"Barnes","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.chest.2018.07.005_bib100","doi-asserted-by":"crossref","first-page":"e1001621","DOI":"10.1371\/journal.pmed.1001621","article-title":"Lung function and incidence of chronic obstructive pulmonary disease after improved cooking fuels and kitchen ventilation: a 9-year prospective cohort study","volume":"11","author":"Zhou","year":"2014","journal-title":"PLoS Med"},{"issue":"5","key":"10.1016\/j.chest.2018.07.005_bib101","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S2213-2600(18)30102-4","article-title":"Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial","volume":"6","author":"Calverley","year":"2018","journal-title":"Lancet Respir Med"},{"issue":"4","key":"10.1016\/j.chest.2018.07.005_bib102","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1183\/09031936.00136014","article-title":"Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4)","volume":"45","author":"Buhl","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.chest.2018.07.005_bib103","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.2147\/COPD.S108758","article-title":"Efficacy and safety of tiotropium\u00a0+ olodaterol maintenance treatment in patients with COPD in the TONADO(R) and OTEMTO(R) studies: a subgroup analysis by age","volume":"11","author":"Ferguson","year":"2016","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.chest.2018.07.005_bib104","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.2147\/DDDT.S39449","article-title":"New developments in the combination treatment of COPD: focus on umeclidinium\/vilanterol","volume":"7","author":"Cazzola","year":"2013","journal-title":"Drug Des Devel Ther"},{"issue":"3","key":"10.1016\/j.chest.2018.07.005_bib105","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S2213-2600(13)70052-3","article-title":"Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study","volume":"1","author":"Wedzicha","year":"2013","journal-title":"Lancet Respir Med"},{"issue":"4","key":"10.1016\/j.chest.2018.07.005_bib106","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1183\/09031936.00004907","article-title":"Inhibition of allergen-induced airway remodelling by tiotropium and budesonide: a comparison","volume":"30","author":"Bos","year":"2007","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.chest.2018.07.005_bib107","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1378\/chest.108.6.1568","article-title":"Inhaled budesonide therapy for patients with stable COPD","volume":"108","author":"Weiner","year":"1995","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.chest.2018.07.005_bib108","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1378\/chest.124.4.1350","article-title":"Withdrawal from treatment as an outcome in the ISOLDE study of COPD","volume":"124","author":"Calverley","year":"2003","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.chest.2018.07.005_bib109","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1183\/09031936.03.00013303","article-title":"Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations","volume":"21","author":"Jones","year":"2003","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.chest.2018.07.005_bib110","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1080\/15412550903140881","article-title":"Effect of fluticasone propionate\/salmeterol (250\/50) on COPD exacerbations and impact on patient outcomes","volume":"6","author":"Anzueto","year":"2009","journal-title":"COPD"},{"issue":"7","key":"10.1016\/j.chest.2018.07.005_bib111","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1513\/pats.200603-096SS","article-title":"Pharmacotherapy for mortality reduction in chronic obstructive pulmonary disease","volume":"3","author":"Sin","year":"2006","journal-title":"Proc Am Thorac Soc"},{"issue":"3","key":"10.1016\/j.chest.2018.07.005_bib112","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1136\/eb-2013-101695","article-title":"Inhaled fluticasone and budesonide increased the risk of serious pneumonia in COPD","volume":"19","author":"White","year":"2014","journal-title":"Evid Based Med"},{"issue":"3","key":"10.1016\/j.chest.2018.07.005_bib113","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1183\/09031936.00193908","article-title":"Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results","volume":"34","author":"Crim","year":"2009","journal-title":"Eur Respir J"},{"issue":"11","key":"10.1016\/j.chest.2018.07.005_bib114","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1136\/thoraxjnl-2012-202872","article-title":"Inhaled corticosteroids in COPD and the risk of serious pneumonia","volume":"68","author":"Suissa","year":"2013","journal-title":"Thorax"},{"issue":"4","key":"10.1016\/j.chest.2018.07.005_bib115","doi-asserted-by":"crossref","first-page":"JC2","DOI":"10.7326\/0003-4819-156-4-201202210-02012","article-title":"ACP Journal Club. Prior use of inhaled corticosteroids was associated with less mortality in elders with COPD and pneumonia","volume":"156","author":"Stanbrook","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.chest.2018.07.005_bib116","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.rmed.2017.07.060","article-title":"Pneumonia risk with inhaled fluticasone furoate and vilanterol in COPD patients with moderate airflow limitation: The SUMMIT trial","volume":"131","author":"Crim","year":"2017","journal-title":"Respir Med"},{"issue":"8","key":"10.1016\/j.chest.2018.07.005_bib117","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1164\/rccm.200904-0492OC","article-title":"Efficacy and tolerability of budesonide\/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease","volume":"180","author":"Welte","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.chest.2018.07.005_bib118","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1183\/13993003.01644-2015","article-title":"Lung function changes over time following withdrawal of inhaled corticosteroids in patients with severe COPD","volume":"47","author":"Magnussen","year":"2016","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.chest.2018.07.005_bib119","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1056\/NEJMoa1407154","article-title":"Withdrawal of inhaled glucocorticoids and exacerbations of COPD","volume":"371","author":"Magnussen","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.chest.2018.07.005_bib120","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.2147\/COPD.S106142","article-title":"Daily home-based spirometry during withdrawal of inhaled corticosteroid in severe to very severe chronic obstructive pulmonary disease","volume":"11","author":"Rodriguez-Roisin","year":"2016","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"8","key":"10.1016\/j.chest.2018.07.005_bib121","first-page":"581","article-title":"The Canadian Optimal Therapy of COPD Trial: design, organization and patient recruitment","volume":"11","author":"Aaron","year":"2004","journal-title":"Can Respir J"},{"issue":"10125","key":"10.1016\/j.chest.2018.07.005_bib122","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/S0140-6736(18)30206-X","article-title":"Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial","volume":"391","author":"Papi","year":"2018","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.chest.2018.07.005_bib123","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJM198906083202304","article-title":"A\u00a0randomized, controlled trial of theophylline in patients with severe chronic obstructive pulmonary disease","volume":"320","author":"Murciano","year":"1989","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.chest.2018.07.005_bib124","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.rmed.2006.09.012","article-title":"The additive effect of theophylline on a combination of formoterol and tiotropium in stable COPD: a pilot study","volume":"101","author":"Cazzola","year":"2007","journal-title":"Respir Med"},{"issue":"6","key":"10.1016\/j.chest.2018.07.005_bib125","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1378\/chest.119.6.1661","article-title":"Salmeterol plus theophylline combination therapy in the treatment of COPD","volume":"119","author":"ZuWallack","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.chest.2018.07.005_bib126","doi-asserted-by":"crossref","first-page":"180010","DOI":"10.1183\/16000617.0010-2018","article-title":"Efficacy and safety profile of xanthines in COPD: a network meta-analysis","volume":"27","author":"Cazzola","year":"2018","journal-title":"Eur Respir Rev"},{"issue":"3","key":"10.1016\/j.chest.2018.07.005_bib127","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1183\/09031936.00178710","article-title":"Roflumilast with long-acting beta2-agonists for COPD: influence of exacerbation history","volume":"38","author":"Bateman","year":"2011","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.chest.2018.07.005_bib128","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1164\/rccm.200610-1563OC","article-title":"Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease","volume":"176","author":"Calverley","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"issue":"9691","key":"10.1016\/j.chest.2018.07.005_bib129","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0140-6736(09)61252-6","article-title":"Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials","volume":"374","author":"Fabbri","year":"2009","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.chest.2018.07.005_bib130","doi-asserted-by":"crossref","first-page":"E1720","DOI":"10.1210\/jc.2011-2886","article-title":"Effect of the phosphodiesterase 4 inhibitor roflumilast on glucose metabolism in patients with treatment-naive, newly diagnosed type 2 diabetes mellitus","volume":"97","author":"Wouters","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.chest.2018.07.005_bib131","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1378\/chest.12-2332","article-title":"Cardiovascular safety in patients receiving roflumilast for the treatment of COPD","volume":"144","author":"White","year":"2013","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.chest.2018.07.005_bib132","doi-asserted-by":"crossref","first-page":"196","DOI":"10.7326\/0003-4819-106-2-196","article-title":"Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease","volume":"106","author":"Anthonisen","year":"1987","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.chest.2018.07.005_bib133","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1378\/chest.117.5.1345","article-title":"Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD","volume":"117","author":"Adams","year":"2000","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.chest.2018.07.005_bib134","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/S0149-2918(03)80095-4","article-title":"A\u00a0comparison of 5-day courses of dirithromycin and azithromycin in the treatment of acute exacerbations of chronic obstructive pulmonary disease","volume":"25","author":"Castaldo","year":"2003","journal-title":"Clin Ther"},{"issue":"8","key":"10.1016\/j.chest.2018.07.005_bib135","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1056\/NEJMoa1104623","article-title":"Azithromycin for prevention of exacerbations of COPD","volume":"365","author":"Albert","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.chest.2018.07.005_bib136","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1164\/rccm.200801-145OC","article-title":"Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations","volume":"178","author":"Seemungal","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"issue":"21","key":"10.1016\/j.chest.2018.07.005_bib137","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1001\/jama.2014.4304","article-title":"Association of azithromycin with mortality and cardiovascular events among older patients hospitalized with pneumonia","volume":"311","author":"Mortensen","year":"2014","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.chest.2018.07.005_bib138","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02265-2016","article-title":"Management of COPD exacerbations: a European Respiratory Society\/American Thoracic Society guideline","volume":"50","author":"Wedzicha","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.chest.2018.07.005_bib139","first-page":"CD001288","article-title":"Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease","author":"Wood-Baker","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"issue":"26","key":"10.1016\/j.chest.2018.07.005_bib140","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1056\/NEJMcp0900449","article-title":"Clinical practice. Alpha1-antitrypsin deficiency","volume":"360","author":"Silverman","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.chest.2018.07.005_bib141","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1164\/ajrccm.160.5.9901055","article-title":"A\u00a0randomized clinical trial of alpha(1)-antitrypsin augmentation therapy","volume":"160","author":"Dirksen","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"10.1016\/j.chest.2018.07.005_bib142","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/S2213-2600(14)70225-5","article-title":"Benralizumab: for asthma, not yet for COPD","volume":"2","author":"Fabbri","year":"2014","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.chest.2018.07.005_bib143","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.2147\/COPD.S129787","article-title":"Relationship between blood eosinophils, clinical characteristics, and mortality in patients with COPD","volume":"12","author":"Zysman","year":"2017","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"5","key":"10.1016\/j.chest.2018.07.005_bib144","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01162-2017","article-title":"Prevalence of persistent blood eosinophilia: relation to outcomes in patients with COPD","volume":"50","author":"Casanova","year":"2017","journal-title":"Eur Respir J"}],"container-title":["Chest"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369218310614?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369218310614?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T08:06:34Z","timestamp":1757923594000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369218310614"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":144,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S0012369218310614"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2018.07.005","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological Therapy of COPD","name":"articletitle","label":"Article Title"},{"value":"Chest","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2018.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Inc under license from the American College of Chest Physicians.","name":"copyright","label":"Copyright"}]}}